Early Detection of Disease Progression in Metastatic Cancers: Could CTCs Improve RECIST Criteria?
Early detection of disease progression is a crucial issue in the management of cancer patients, especially in metastatic settings. Currently, treatment selection mostly relies on criteria based on radiologic evaluations (RECIST). The aim of the present retrospective study is to evaluate the potentia...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-02-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/12/2/388 |
| _version_ | 1797298839356440576 |
|---|---|
| author | Valentina Magri Luca Marino Gianluigi De Renzi Michela De Meo Francesca Salvatori Dorelsa Buccilli Vincenzo Bianco Daniele Santini Chiara Nicolazzo Paola Gazzaniga |
| author_facet | Valentina Magri Luca Marino Gianluigi De Renzi Michela De Meo Francesca Salvatori Dorelsa Buccilli Vincenzo Bianco Daniele Santini Chiara Nicolazzo Paola Gazzaniga |
| author_sort | Valentina Magri |
| collection | DOAJ |
| description | Early detection of disease progression is a crucial issue in the management of cancer patients, especially in metastatic settings. Currently, treatment selection mostly relies on criteria based on radiologic evaluations (RECIST). The aim of the present retrospective study is to evaluate the potential inclusion of circulating tumor cells (CTCs) in hybrid criteria. CTC counts from a total of 160 patients with different metastatic tumors were analyzed for this purpose. In our cohort, 73 patients were affected by breast cancer, 69 by colorectal cancer and 18 by prostate cancer. PFS and OS were evaluated according to the corresponding prediction of disease progression by CTCs and RECIST criteria. In breast cancer, CTC-I has an important impact on the progression-free survival (PFS) and overall survival (OS) values. When CTC-I predicted earlier than RECIST-I, the disease progression, the PFS and OS were shorter with respect to the opposite case. In particular, PFS was 11 (5–16) vs. 34 (23–45)—with <i>p</i> < 0.001—and OS was 80 (22–138) vs. 116 (43–189), <i>p</i> = 0.33. The results suggest a promising role of CTCs as complementary information which could significantly improve the clinical outcomes, and they encourage consideration of future trials to evaluate new hybrid criteria, particularly for patients with breast cancer. |
| first_indexed | 2024-03-07T22:40:53Z |
| format | Article |
| id | doaj.art-a2193c37bea7439a8e417c4e8db1c303 |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-07T22:40:53Z |
| publishDate | 2024-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-a2193c37bea7439a8e417c4e8db1c3032024-02-23T15:08:41ZengMDPI AGBiomedicines2227-90592024-02-0112238810.3390/biomedicines12020388Early Detection of Disease Progression in Metastatic Cancers: Could CTCs Improve RECIST Criteria?Valentina Magri0Luca Marino1Gianluigi De Renzi2Michela De Meo3Francesca Salvatori4Dorelsa Buccilli5Vincenzo Bianco6Daniele Santini7Chiara Nicolazzo8Paola Gazzaniga9Department of Pathology, Oncology and Radiology, Sapienza University of Rome, 00161 Rome, ItalyDepartment of Mechanical and Aerospace Engineering, Sapienza University of Rome, 00161 Rome, ItalyDepartment of Molecular Medicine, Sapienza University of Rome, 00161 Rome, ItalyDepartment of Molecular Medicine, Sapienza University of Rome, 00161 Rome, ItalyDepartment of Pathology, Oncology and Radiology, Sapienza University of Rome, 00161 Rome, ItalyDepartment of Pathology, Oncology and Radiology, Sapienza University of Rome, 00161 Rome, ItalyDepartment of Pathology, Oncology and Radiology, Sapienza University of Rome, 00161 Rome, ItalyDepartment of Pathology, Oncology and Radiology, Sapienza University of Rome, 00161 Rome, ItalyDepartment of Molecular Medicine, Sapienza University of Rome, 00161 Rome, ItalyDepartment of Molecular Medicine, Sapienza University of Rome, 00161 Rome, ItalyEarly detection of disease progression is a crucial issue in the management of cancer patients, especially in metastatic settings. Currently, treatment selection mostly relies on criteria based on radiologic evaluations (RECIST). The aim of the present retrospective study is to evaluate the potential inclusion of circulating tumor cells (CTCs) in hybrid criteria. CTC counts from a total of 160 patients with different metastatic tumors were analyzed for this purpose. In our cohort, 73 patients were affected by breast cancer, 69 by colorectal cancer and 18 by prostate cancer. PFS and OS were evaluated according to the corresponding prediction of disease progression by CTCs and RECIST criteria. In breast cancer, CTC-I has an important impact on the progression-free survival (PFS) and overall survival (OS) values. When CTC-I predicted earlier than RECIST-I, the disease progression, the PFS and OS were shorter with respect to the opposite case. In particular, PFS was 11 (5–16) vs. 34 (23–45)—with <i>p</i> < 0.001—and OS was 80 (22–138) vs. 116 (43–189), <i>p</i> = 0.33. The results suggest a promising role of CTCs as complementary information which could significantly improve the clinical outcomes, and they encourage consideration of future trials to evaluate new hybrid criteria, particularly for patients with breast cancer.https://www.mdpi.com/2227-9059/12/2/388metastatic cancerscirculating tumor cellsRECIST criteriadisease progressionpersonalized oncology |
| spellingShingle | Valentina Magri Luca Marino Gianluigi De Renzi Michela De Meo Francesca Salvatori Dorelsa Buccilli Vincenzo Bianco Daniele Santini Chiara Nicolazzo Paola Gazzaniga Early Detection of Disease Progression in Metastatic Cancers: Could CTCs Improve RECIST Criteria? Biomedicines metastatic cancers circulating tumor cells RECIST criteria disease progression personalized oncology |
| title | Early Detection of Disease Progression in Metastatic Cancers: Could CTCs Improve RECIST Criteria? |
| title_full | Early Detection of Disease Progression in Metastatic Cancers: Could CTCs Improve RECIST Criteria? |
| title_fullStr | Early Detection of Disease Progression in Metastatic Cancers: Could CTCs Improve RECIST Criteria? |
| title_full_unstemmed | Early Detection of Disease Progression in Metastatic Cancers: Could CTCs Improve RECIST Criteria? |
| title_short | Early Detection of Disease Progression in Metastatic Cancers: Could CTCs Improve RECIST Criteria? |
| title_sort | early detection of disease progression in metastatic cancers could ctcs improve recist criteria |
| topic | metastatic cancers circulating tumor cells RECIST criteria disease progression personalized oncology |
| url | https://www.mdpi.com/2227-9059/12/2/388 |
| work_keys_str_mv | AT valentinamagri earlydetectionofdiseaseprogressioninmetastaticcancerscouldctcsimproverecistcriteria AT lucamarino earlydetectionofdiseaseprogressioninmetastaticcancerscouldctcsimproverecistcriteria AT gianluigiderenzi earlydetectionofdiseaseprogressioninmetastaticcancerscouldctcsimproverecistcriteria AT michelademeo earlydetectionofdiseaseprogressioninmetastaticcancerscouldctcsimproverecistcriteria AT francescasalvatori earlydetectionofdiseaseprogressioninmetastaticcancerscouldctcsimproverecistcriteria AT dorelsabuccilli earlydetectionofdiseaseprogressioninmetastaticcancerscouldctcsimproverecistcriteria AT vincenzobianco earlydetectionofdiseaseprogressioninmetastaticcancerscouldctcsimproverecistcriteria AT danielesantini earlydetectionofdiseaseprogressioninmetastaticcancerscouldctcsimproverecistcriteria AT chiaranicolazzo earlydetectionofdiseaseprogressioninmetastaticcancerscouldctcsimproverecistcriteria AT paolagazzaniga earlydetectionofdiseaseprogressioninmetastaticcancerscouldctcsimproverecistcriteria |